ADAM10 and central nervous system cancer: In vitro studies reported that ADAM10 and ADAM17 inhibition selectively increases glioma sphere-forming cells but not neural stem cell migration and that the migrated GSCs exhibit a differentiated phenotype, suggesting a role in retaining the cells in the tumorigenic environment in an undifferentiated state [63,64].